On November 8, 2021 Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, reported that Janux management will participate in fireside chats at two upcoming virtual investor conferences (Press release, Janux Therapeutics, NOV 8, 2021, View Source [SID1234594748]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cowen’s 5th Annual IO Next Summit
Forum: Fireside Chat
Date: Monday, November 15th, 2021
Time: 12:15-12:35 p.m. ET

Evercore ISI 4th Annual Health CONx Virtual Conference
Forum: Fireside Chat
Date: Thursday, December 2nd, 2021
Time: 2:40 – 3:00 p.m. ET

Both fireside chats and subsequent archived replays may be accessed via the Investors & Media section of Janux’s website. An archived replay of both webcasts will be available on the website for approximately 90 days following the presentation.